Hot topics | Coronavirus pandemic

SXT Pharmaceuticals, Inc. has added a newly formulated Kuihuapan and Zhudanfen Advanced TCMP Products, and Announced its Expected Continuous Growth of Its Production Capacity of Luxuejin

SXT Pharmaceuticals, Inc. has added a newly formulated Kuihuapan and Zhudanfen Advanced TCMP Products, and Announced its Expected Continuous Growth of Its Production Capacity of Luxuejin

The Kuihuapan After-Soaking-Oral TCMP and Zhudanfen are widely available in China, according to the National Medical Insurance Catalogue (NO 697).

The Company's new lyophilization production facilities have been canceled due to a GMP compliance audit conducted by the Jiangsu Province Medical Products Administration (JSMPA) in June 2021. The total amount of Luxuejin following a freeze-drying is 316.92 kilogram, which is expected to gain worldwide sales by March 31, 2022.

The R&D Department of China systematically developed a new type of After-Soaking-Oral TCMP product that can be boiled directly orally or infused without decoction, and maintains all the original effective ingredients.

"The development of the R&D and the production of Advanced TCMP products will greatly help us make continuous efforts in driving the R&D of Advanced TCMP and pursuing high-quality products.", according to Feng Zhou, China SXT's Chief Executive Officer.

SXT Pharmaceuticals, Inc., China SXT Pharmaceuticals, Inc.

SXT Pharmaceuticals, Inc. was established in 2005 and has a manufacturing facility in Taizhou City, Jiangsu Province, China. It is a leading pharmaceutical company focusing on the research, development, manufacture, and marketing of traditional Chinese medicine products, which has been processed to be ready for use.

Statement on Safe Harbor

These forward-looking statements are subject to uncertainties and uncertainties, including, but not limited to, the Company's future business development, product and service demand and acceptance, and changes in technology.

SOURCE China SXT Pharmaceuticals, Inc.

You may also like: